LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
THIS LOAN AND SECURITY AGREEMENT (as the same may from time to time be amended, modified, supplemented or restated, this “Agreement”) dated as of March 31, 2015 (the “Effective Date”) among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 hereof or otherwise a party hereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 110, LP, a Delaware limited pa
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
This Executive Employment Agreement (this “Agreement”) is effective as of January 1, 2019 (the “Effective Date”) by and between Inhibrx, Inc., a Delaware corporation (the “Company”), and Brendan Eckelman (“Executive”).
SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS SECOND AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of December 22, 2016 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 110, LP, a Delaware limited partnership, INBRX 111, LP, a Delaware li
FIRST AMENDMENT, WAIVER AND CONSENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS FIRST AMENDMENT, WAIVER AND CONSENT to the Loan and Security Agreement (this “Amendment”) is entered into as of August 15, 2016 (the “First Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (“Oxford”), as collateral agent (in such capacity, “Collateral Agent”), the Lenders listed on Schedule 1.1 of the Loan Agreement (as defined below) or otherwise a party thereto from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), and ”), and Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 1
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
This License Agreement (“Agreement”) is made and entered into as of the 28th day of February 2018, Pacific Standard time (the “Effective Date”) by and between Elpiscience Biopharmaceuticals, Inc., a Cayman Islands company having offices at Offices of Corporate Filing Services Ltd., 3rd Floor, Harbour Centre, George Town, P.O. Box 613, Grand Cayman KY1-1107, Cayman Islands (“Elpiscience”) and Inbrx105 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Elpiscience and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (this “Agreement”) is made effective e as of July 1, 2013 (“Effective Date”) by and between INBRX 103, LLC, a limited liability company with an address at 11099 North Torrey Pines Road, Suite 130, La Jolla, CA 92037 (“Inhibrx”), and Celgene Corporation a Delaware corporation with an address at 86 Morris Avenue, Summit, NJ 07901 (“Licensee”). Inhibrx and Licensee each may be referred to herein individually as a “Party” and together as the “Parties.”
FIRST AMENDMENT TO LEASELease • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This FIRST AMENDMENT TO LEASE (“First Amendment”) is made and entered into as of May 21, 2019, by and between HCP TPSP, LLC, a Delaware limited liability company (“Landlord”), and INHIBRX, INC., a Delaware corporation (“Tenant”).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
This License Agreement (this “Agreement”), effective as of December 20, 2018 (the “Effective Date”), is entered into by and between Inhibrx, Inc., a Delaware corporation (“Inhibrx”), and bluebird bio, Inc., a Delaware corporation (“Licensee”). Inhibrx and Licensee are referred to individually as a “Party” and collectively as the “Parties.”
RESTRICTED STOCK AGREEMENT INHIBRX, INC.Restricted Stock Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
AGREEMENT made as of the [ ] day of [ ], 20[ ] (the “Grant Date”), between Inhibrx, Inc. (the “Company”), a Delaware corporation, and [ ] (the “Participant”).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...License Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
This License Agreement (“Agreement”) is made and entered into as of the 21st day of June 2017, New York Time (the “Effective Date”) by and between Hangzhou Just Biotherapeutics Co., Ltd., a limited liability company having offices at 11/F, Building 5, No.2 Ke Ji Yuan Road, Hangzhou Eco-Tech Development Area, Hangzhou, China, 310018 (“Just”) and Inbrx109 LP (“Inhibrx”), a Delaware limited partnership with an address at 11099 North Torrey Pines Road, Suite 280, La Jolla, CA 92037. Just and Inhibrx are each referred to herein individually as a “Party” and collectively as the “Parties.”
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...Master Services Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances)
This Amended and Restated Master Services Agreement (“Agreement”) is dated August 28, 2018 (the “Restated Effective Date”) and is between Inhibrx, Inc. (“Client”) and WuXi Biologics (Hong Kong) Limited (“Provider”).
Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be...Option Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • New York
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of the day of [ ], 2019, by and among Inhibrx, Inc., a Delaware corporation formerly known as Tenium Therapeutics, Inc. (the “Company”), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor”, each of the stockholders listed on Schedule B hereto, each of whom is referred to herein as a “Key Holder” and any Future Purchaser (as defined below) that becomes a party to this Agreement in accordance with Section 6.9 hereof.
CONSENT AND THIRD AMENDMENT TO LOAN AND SECURITY AGREEMENTLoan and Security Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • Delaware
THIS CONSENT AND THIRD AMENDMENT to Loan and Security Agreement (this “Amendment”) is entered into as of April 30, 2018 (the “Amendment Date”), by and among OXFORD FINANCE LLC, a Delaware limited liability company with an office located at 133 North Fairfax Street, Alexandria, Virginia 22314 (in its individual capacity, “Oxford”; and in its capacity as Collateral Agent, “Collateral Agent”), the Lenders listed on Schedule 1.1 thereof from time to time including Oxford in its capacity as a Lender (each a “Lender” and collectively, the “Lenders”), Inhibrx, LP, a Delaware limited partnership, Inhibrx 101, LP, a Delaware limited partnership, Inhibrx 104, LP, a Delaware limited partnership, INBRX 105, LP, a Delaware limited partnership, INBRX 106, LP, a Delaware limited partnership, INBRX 107, LP, a Delaware limited partnership, INBRX 108, LP, a Delaware limited partnership, INBRX 109, LP, a Delaware limited partnership, INBRX 110, LP, a Delaware limited partnership, INBRX 111, LP, a Delawar
FIRST AMENDMENT TO RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENTSale Agreement • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
THIS FIRST AMENDMENT TO RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT (this “Amendment”), is made and effective as of May 20, 2019 (the “Effective Date”), to amend that certain Right of First Refusal and Co-Sale Agreement, dated as of April 30, 2018 (the “ROFR Agreement”), by and among Inhibrx, Inc., a Delaware corporation formerly known as Tenium Therapeutics, Inc. (the “Company”), the Investors and Common Holders party thereto. Capitalized terms used but not defined herein shall have the meanings given to them in the ROFR Agreement.
SUMMARY OF BASIC LEASE INFORMATIONLease • June 3rd, 2019 • Inhibrx, Inc. • Biological products, (no disgnostic substances) • California
